|
|
||||||||
1 Laboratory of Applied Biochemistry, Department of Biology, Faculty of Sciences, University Ferhat Abbas of Setif, Algeria
2 Laboratory of Biochemistry, Faculty of Life and Nature Sciences, University of Bejaia, Algeria
3 Department of Biology and Biochemistry, University of Bath, UK
Corresponding author: M. Benboubetra; e-mail: benboubetra{at}yahoo.co.uk.
Xanthine oxidoreductase (XOR) was purified for the first time from sheeps milk. The ultraviolet-visible absorption spectrum was essentially identical to those of the corresponding bovine, human, and goats milk enzymes and showed an A280/A450 ratio of 5.35 ± 0.24, indicating a high degree of purity. Like milk XOR from other species, sheeps milk enzyme showed a single band on SDS-PAGE corresponding to a subunit with approximate Mr 150,000. Xanthine oxidase activity of purified sheeps milk XOR (0.69 ± 0.04 µmole urate min1 mg1) was low relative to that of the bovine milk enzyme (1.83 ± 0.02 µmole urate min1 mg1), but higher than those of human or goats milk XOR. As in the latter 2 cases, the low activity of sheeps milk XOR can be attributed to its relatively low molybdenum content (0.18 atoms per subunit), compared with that of the bovine milk enzyme (0.56 atoms Mo per subunit). Consistent with this, NADH oxidase activity of sheeps milk XOR was similar to that of enzymes purified from bovine, human, or goats milk. The presence of desulpho-enzyme in sheeps milk XOR was demonstrated by resulfuration experiments, whereby xanthine oxidase activity was increased by approximately 75%.
Key Words: molybdenum NADH oxidase sheeps milk xanthine oxidoreductase
Abbreviation key: MFGM = milk fat globule membrane, NAD+(H) = nicotinamide adenine dinucleotide (reduced), PFR = protein/flavine ratio, ROS = reactive oxygen species, XDH = xanthine dehydrogenase, XO = xanthine oxidase, XOR = xanthine oxidoreductase
This article has been cited by other articles:
![]() |
M. L. de Lemos, L. Hamata, S. Jennings, and T. Leduc Interaction between mercaptopurine and milk Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 237 - 240. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |